Recursion overhauls pipeline after key drug fails in mid-stage trial
Endpoints News - 05-May-2025With $509M in cash, biotech bets on fewer, stronger programs ahead of 2025 data
Join the club for FREE to access the whole archive and other member benefits.
Biopharma correspondent
Andrew Dunn is a senior biopharma correspondent, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. His reporting interests include AI's emerging role in biotech, cell and gene therapy, and how money and medicine mix. Based in New York City, he joined Endpoints News in 2023, previously reporting on biotech at Business Insider and BioPharma Dive. His work has been cited by news outlets including the Washington Post, CNN, and the New York Times. He’s also appeared on CNBC, C-SPAN, and MSNBC to discuss his work. Dunn graduated from the University of Maryland, College Park, majoring in journalism and economics.
Visit website: https://endpts.com/author/andrew-dunn/
See alsoDetails last updated 15-Dec-2024
With $509M in cash, biotech bets on fewer, stronger programs ahead of 2025 data
AI startup decodes live cell behaviour using simple imaging and machine learning
Tune Therapeutics secures $175M to pioneer precise gene modulation therapies
This aims to reduce development time but faces challenges in proving real-world success
New AI model enhances drug success with precise predictions